Yes / Ciprofloxacin (CIP) is a poorly soluble drug that also displays poor permeability. Attempts to improve the solubility of this drug to date have largely focused on the formation of crystalline salts and metal complexes. The aim of this study was to prepare amorphous solid dispersions (ASDs) by ball milling CIP with various polymers. Following examination of their solid state characteristics and physical stability, the solubility advantage of these ASDs was studied, and their permeability was investigated via parallel artificial membrane permeability assay (PAMPA). Finally, the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the ASDs were compared to those of CIP. It was discovered that acidic polymers, such as Eudragit L100, Eudragit L100C==, Carbopol and HPMCAS, were necessary for the amorphization of CIP. In each case, the positively charged secondary amine of CIP was found to interact with carboxylate groups in the polymers, forming amorphous polymeric drug salts. Although the ASDs began to crystallize within days under accelerated stability conditions, they remained fully XCray amorphous following exposure to 90% RH at 25 oC, and demonstrated higher than predicted glass transition temperatures. The solubility of CIP in water and simulated intestinal fluid was also increased by all of the ASDs studied. Unlike a number of other solubility enhancing formulations, the ASDs did not decrease the permeability of the drug. Similarly, no decrease in antibiotic efficacy was observed, and significant improvements in the MIC and MBC of CIP were obtained with ASDs containing HPMCASC") and HPMCASCMG. Therefore, ASDs may be a viable alternative for formulating CIP with improved solubility, bioavailability and antimicrobial activity.

The unique symmetry requirements of second harmonic generation (SHG) provide exquisite selectivity to chiral crystals, enabling independent quantitative modeling of the nucleation and crystal growth of active pharmaceutical ingredients (APIs) within amorphous solid dispersions (ASDs) during accelerated in situ stability testing, and in vitro dissolution testing. ASDs, in which an API is maintained in an amorphous state within a polymer matrix, are finding increasing use to address solubility limitations of small-molecule APIs. SHG microscopy yielded limits of detection for ritonavir crystals as low as 10 ppm, which is about two orders of magnitude lower than other methods currently available for crystallinity detection in ASDs. The quantitative capabilities of SHG analysis were substantially improved further while simultaneously dramatically reducing the total sample volume and storage burden through in situ analysis. Single particle tracking of crystal growth performed in situ enabled substantial improvements in the signal to noise ratio (SNR) for recovered crystal nucleation and growth rates by nonlinear optical microscopy. Upon dissolution, the presence of solubilizing additives in biorelevant media greatly affected the generation and stabilization of supersaturated solutions. SHG microscopy was found to enable the detection of crystals even in the highly turbid Ensure Plus® system. Analysis of the SHG micrographs clearly indicated that differences in the nucleation kinetics rather than growth rates dominated the overall trends in crystallinity. For weakly basic drugs, the fate of dissolution in fasted-state simulated intestinal fluid (FaSSIF, pH 6.5) varied with the ASDs drug loading, and was highly affected by the pre-exposure to the fasted-state simulated gastric fluid (FaSSGF, pH 1.6) medium, versus the dissolution in FaSSIF medium alone. The presence of crystals during the first stage of posaconazole ASDs dissolution in FaSSGF acted as nuclei for further crystallization in the later dissolution stage in FaSSIF. The results provide insights of better formulation prediction of poorly soluble drugs, as well as understanding origins of intraluminal absorption variability for such systems

Yes / A study has been carried out to investigate controlled release performance of caplet shaped injection moulded (IM) amorphous solid dispersion (ASD) tablets based on the model drug AZD0837 and polyethylene oxide (PEO). The physical/chemical storage stability and release robustness of the IM tablets were characterized and compared to that of conventional extended release (ER) hydrophilic matrix tablets of the same raw materials and compositions manufactured via direct compression (DC). To gain an improved understanding of the release mechanisms, the dissolution of both the polymer and the drug were studied. Under conditions where the amount of dissolution media was limited, the controlled release ASD IM tablets demonstrated complete and synchronized release of both PEO and AZD0837 whereas the release of AZD0837 was found to be slower and incomplete from conventional direct compressed ER hydrophilic matrix tablets. Results clearly indicated that AZD0837 remained amorphous throughout the dissolution process and was maintained in a supersaturated state and hence kept stable with the aid of the polymeric carrier when released in a synchronized manner. In addition, it was found that the IM tablets were robust to variation in hydrodynamics of the environment and PEO molecular weight. / The research was funded by AstraZeneca, Sweden.